Zobrazeno 1 - 10
of 557
pro vyhledávání: '"Ganetespib"'
Autor:
Sameh Saber, Alexandru Madalin Hasan, Osama A. Mohammed, Lobna A. Saleh, Abdullah A. Hashish, Mohannad Mohammad S. Alamri, Ahmed Y. Al-Ameer, Jaber Alfaifi, Ahmed Senbel, Adel Mohamed Aboregela, Tarig Babikir Algak Khalid, Mustafa Ahmed Abdel-Reheim, Simona Cavalu
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 164, Iss , Pp 114918- (2023)
Sorafenib, a multikinase inhibitor, is a first-line treatment for advanced hepatocellular carcinoma, but its long-term effectiveness is limited by the emergence of resistance mechanisms. One such mechanism is the reduction of microvessel density and
Externí odkaz:
https://doaj.org/article/f7f371d484264f839bc894674231ff64
Autor:
Simon Deycmar, Elisabeth Mara, Sylvia Kerschbaum-Gruber, Verena Waller, Dietmar Georg, Martin Pruschy
Publikováno v:
Radiation Oncology, Vol 17, Iss 1, Pp 1-17 (2022)
Abstract Objective Hypersensitivity towards proton versus photon irradiation was demonstrated in homologous recombination repair (HRR)-deficient cell lines. Hence, combined treatment concepts targeting HRR provide a rational for potential pharmaceuti
Externí odkaz:
https://doaj.org/article/5e7e5ab9a4b44a9eb88a9cbed686867f
Autor:
Wenchong Tan, Jinxin Zhang, Lixia Liu, Manfeng Liang, Jieyou Li, Zihao Deng, Zhenming Zheng, Yaotang Deng, Chenyang Liu, Yan Li, Guantai Xie, Jiajie Zhang, Fei Zou, Xuemei Chen
Publikováno v:
Translational Oncology, Vol 26, Iss , Pp 101502- (2022)
Heat shock protein 90 (Hsp90) has been an important therapeutic target for cancer therapy for decades. Unexpectedly, the monotherapy of N-terminal Hsp90 inhibitor STA9090 related clinical trials halted in phase III, and metastases were reported in an
Externí odkaz:
https://doaj.org/article/225437e965bb47dc8cae4a6d42c9ead7
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Mantle cell lymphoma (MCL) is a highly aggressive and heterogeneous B-cell lymphoma. Though Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has shown great efficacy as a single agent for MCL treatment, the real-world use of ibrutinib is still su
Externí odkaz:
https://doaj.org/article/9eab01066f3a43e1821901f5366b2932
Autor:
Gehad Subaiea, Syed Mohd Danish Rizvi, Hemant Kumar Singh Yadav, Turki Al Hagbani, Marwa Helmy Abdallah, El-Sayed Khafagy, Hosahalli Veerabhadrappa Gangadharappa, Talib Hussain, Amr Selim Abu Lila
Publikováno v:
Pharmaceuticals, Vol 16, Iss 2, p 230 (2023)
Among the various types of cancer, lung cancer accounts for the highest number of fatalities across the globe. A combination of different cancer chemotherapeutics is regarded as an effective strategy for clinical management of different cancers. Gane
Externí odkaz:
https://doaj.org/article/694e8c54bc504e0da1880f9e33856588
Corrigendum: Effects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans
Publikováno v:
Frontiers in Microbiology, Vol 12 (2021)
Externí odkaz:
https://doaj.org/article/8374146b1188429db194e3c48d91cecd
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Lapatinib is an FDA-approved EGFR and HER2 tyrosine kinase inhibitor for the treatment of HER2-positive breast cancer patients. However, its therapeutic efficacy is limited by primary or acquired resistance. In the present study, we established breas
Externí odkaz:
https://doaj.org/article/82900ebb524c4e0787de8581116b115d
Autor:
Nuramalina H. Mumin, Neele Drobnitzky, Agata Patel, Luiza Madia Lourenco, Fiona F. Cahill, Yanyan Jiang, Anthony Kong, Anderson J. Ryan
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-14 (2019)
Abstract Background Due to the lack of effective therapies and poor prognosis in TNBC (triple-negative breast cancer) patients, there is a strong need to develop effective novel targeted therapies for this subtype of breast cancer. Inhibition of heat
Externí odkaz:
https://doaj.org/article/69534f213e83452c8a4a36b41f55fde1
Publikováno v:
Frontiers in Microbiology, Vol 12 (2021)
Candida albicans is the most common fungal pathogen. Recently, drug resistance of C. albicans is increasingly severe. Hsp90 is a promising antifungal target to overcome this problem. To evaluate the effects of Hsp90 inhibitor ganetespib on the inhibi
Externí odkaz:
https://doaj.org/article/f23347debdbe4eed9739b9739ce90942
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.